Cipla Limited
CIPLA
Rank in Stocks
#1819
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Share Price
$14.61
Market Cap
$11.80B
Change (1 day)
-0.12%
Change (1 year)
-18.47%
Country
IN
Trade Cipla Limited (CIPLA)
Category
Healthcare
P/B ratio for Cipla Limited (CIPLA)
P/B ratio as of October 2026 TTM: 3.11
According to Cipla Limited latest financial reports and stock price the company's current price-to-book ratio (TTM) is 3.11. At the end of 2024 the company had a P/B ratio of 4.53.
P/B ratio history for Cipla Limited from 2004 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.11 | -16.73% |
| 2025 | 3.74 | -17.41% |
| 2024 | 4.53 | 45.93% |
| 2023 | 3.10 | -21.21% |
| 2022 | 3.94 | 9.87% |
| 2021 | 3.59 | 65.87% |
| 2020 | 2.16 | -23.32% |
| 2019 | 2.82 | -13.48% |
| 2018 | 3.26 | -14.25% |
| 2017 | 3.80 | 6.45% |
| 2016 | 3.57 | -32.58% |
| 2015 | 5.30 | 86.12% |
| 2014 | 2.85 | -16.93% |
| 2013 | 3.43 | 6.81% |
| 2012 | 3.21 | -17.22% |
| 2011 | 3.87 | -14.35% |
| 2010 | 4.52 | 14.98% |
| 2009 | 3.93 | -13.61% |
| 2008 | 4.55 | -19.79% |
| 2007 | 5.68 | -43.30% |
| 2006 | 10.01 | 102.81% |
| 2005 | 4.94 | -11.35% |
| 2004 | 5.57 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 61.86% |
IN
|
